NCT06809868 Role of Transposable Elements in Septic Immune Aging
| NCT ID | NCT06809868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 116 participants |
| Start Date | 2025-02-14 |
| Primary Completion | 2028-02-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 116 participants in total. It began in 2025-02-14 with a primary completion date of 2028-02-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is: 1. Do transposable elements prematurely age the immune systems of patients with sepsis? 2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU? 3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU? Participants will have blood drawn from them but will not be subjected to additional interventions.
Eligibility Criteria
Inclusion Criteria: * Age 18 or older * Admitted to ICU with sepsis (Sepsis 3 Criteria) * SOFA score of at least 2 at time of enrollment Exclusion Criteria: * Patients on organ transplantation immunosuppression * Patients with preexisting leukopenia * Cancer patients receiving CAR-T therapy * Patients who are under 18 years of age or otherwise deemed pediatric * Patients with an ongoing bleeding diathesis (ie: DIC, hemorrhagic shock) * Patients with a chronic hemoglobin below 7.0 * Patients who, prior to their ICU admission, are blood transfusion dependent
Contact & Investigator
Alexendar R Perez, M.D., Ph.D
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06809868 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06809868 currently recruiting?
Yes, NCT06809868 is actively recruiting participants. Contact the research team at Alexendar.Perez@ucsf.edu for enrollment information.
Where is the NCT06809868 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06809868 clinical trial?
NCT06809868 is sponsored by University of California, San Francisco. The principal investigator is Alexendar R Perez, M.D., Ph.D at University of California, San Francisco. The trial plans to enroll 116 participants.